The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on Astrocytes
暂无分享,去创建一个
[1] J. S. Schneider,et al. Astrocytic Responses to the Dopaminergic Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Cat and Mouse Brain , 1988, Journal of neuropathology and experimental neurology.
[2] V Balasingam,et al. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[3] M. Ross,et al. Cyclo-Oxygenase-2 Gene Expression in Neurons Contributes to Ischemic Brain Damage , 1997, The Journal of Neuroscience.
[4] Luigi Aloe,et al. TNF-α expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior , 1997, Neuroscience Letters.
[5] P. Damier,et al. Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.
[6] K. Davis,et al. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. , 1998, Archives of general psychiatry.
[7] R. Djaldetti,et al. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] K. Prasad,et al. Multiple antioxidants in the prevention and treatment of Parkinson's disease. , 1999, Journal of the American College of Nutrition.
[9] R. Djaldetti,et al. IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease , 1999 .
[10] M. Sogorb,et al. Dichlorophenyl phosphoramidates as substrates for avian and mammalian liver phosphotriesterases: activity levels, calcium dependence and stereospecificity. , 1999, Chemico-biological interactions.
[11] T. Peng,et al. Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.
[12] S. Mandel,et al. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies , 2000, Journal of Neurology.
[13] P. Mcgeer,et al. R-(−)-Deprenyl Inhibits Monocytic THP-1 Cell Neurotoxicity Independently of Monoamine Oxidase Inhibition , 2000, Experimental Neurology.
[14] H. Ichinose,et al. Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.
[15] A. Minagar,et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis , 2002, Journal of the Neurological Sciences.
[16] J. Cano,et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. , 2002, Journal of neurochemistry.
[17] M. Horne,et al. The Role of Interleukin-1, Interleukin-6, and Glia in Inducing Growth of Neuronal Terminal Arbors in Mice , 2002, The Journal of Neuroscience.
[18] S. Speciale,et al. MPTP: insights into parkinsonian neurodegeneration. , 2002, Neurotoxicology and teratology.
[19] J. Cano,et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .
[20] Andis Klegeris,et al. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity , 2002, Neurobiology of Aging.
[21] E. Hirsch,et al. The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[22] Dong-Kug Choi,et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] S. Allan,et al. The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease. , 2003, Current drug targets. CNS and neurological disorders.
[24] M. Beal. Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[25] P. Carvey,et al. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. , 2003, Frontiers in bioscience : a journal and virtual library.
[26] W. Willett,et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.
[27] M. Barrachina,et al. Dopamine induces autophagic cell death and α‐synuclein increase in human neuroblastoma SH‐SY5Y cells , 2003, Journal of neuroscience research.
[28] L. Minghetti. Cyclooxygenase‐2 (COX‐2) in Inflammatory and Degenerative Brain Diseases , 2004, Journal of neuropathology and experimental neurology.
[29] Ling-chun Chen,et al. Temporal gene expression patterns in G93A/SOD1 mouse , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[30] E. Ongini,et al. Attenuation of chronic neuroinflammation by a nitric oxide‐releasing derivative of the antioxidant ferulic acid , 2004, Journal of neurochemistry.
[31] E. Feldman,et al. Neuroinflammation, COX-2, and ALS—a dual role? , 2004, Experimental Neurology.
[32] C. Asselin,et al. IL-1-dependent regulation of C/EBPd transcriptional activity , 2005 .
[33] F. Breedveld. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept]. , 2005, Nederlands tijdschrift voor geneeskunde.
[34] C. Asselin,et al. IL-1 beta-dependent regulation of C/EBP delta transcriptional activity. , 2005, Biochemical and biophysical research communications.
[35] S. Tzeng,et al. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. , 2005, Current drug targets. Inflammation and allergy.
[36] T. Montine,et al. Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[37] K. Hensley,et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2006, Antioxidants & redox signaling.
[38] A. Favier. Stress oxydant et pathologies humaines , 2006 .
[39] B. Jiang,et al. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures. , 2006, Life sciences.
[40] E. Katunina,et al. [Antioxidants in complex treatment of Parkinson's disease]. , 2006, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[41] W. Kukull,et al. Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[42] W. Tsai,et al. Divergent role of calcium on Abeta- and MPTP-induced cell death in SK-N-SH neuroblastoma. , 2006, Life sciences.
[43] K. Weiss,et al. Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration. , 2006, The Journal of rheumatology.
[44] A. Favier. [Oxidative stress in human diseases]. , 2006, Annales pharmaceutiques francaises.
[45] J. Relton,et al. Neuroinflammation in Parkinson’s patients and MPTP-treated mice is not restricted to the nigrostriatal system: Microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb , 2007, Experimental Gerontology.
[46] V. Cuomo,et al. Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression , 2007 .
[47] G. Bing,et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system , 2007, Journal of neurochemistry.
[48] G. Deuschl,et al. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. , 2007, Current pharmaceutical design.
[49] S. Tufik,et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. , 2007, European journal of pharmacology.
[50] J. Rogers,et al. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.
[51] T. Bisogno,et al. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro , 2007, Journal of Molecular Medicine.
[52] E. Ling,et al. Microglial activation and its implications in the brain diseases. , 2007, Current medicinal chemistry.
[53] W. Marks,et al. Epidemiology of Parkinson's disease. , 2007, Disease-a-month : DM.
[54] V. Cuomo,et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. , 2007, British journal of pharmacology.
[55] Takashi Mori,et al. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2007, Brain Research.
[56] Hong Yuan 袁红,et al. Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes , 2007, Neuroscience Bulletin.
[57] B. Li,et al. The NADPH oxidase is involved in lipopolysaccharide-mediated motor neuron injury , 2008, Brain Research.
[58] D. Doudet,et al. Neuromodulation in a minipig MPTP model of Parkinson disease , 2008, British journal of neurosurgery.
[59] M. Mena,et al. Glial Cells as Players in Parkinsonism: The “Good,” the “Bad,” and the “Mysterious” Glia , 2008, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[60] G. Miller,et al. PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity , 2008, Neuropeptides.
[61] A. Stępień,et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.
[62] S. Przedborski,et al. Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.
[63] M. Mena,et al. Glial Dysfunction in Parkin Null Mice: Effects of Aging , 2008, The Journal of Neuroscience.
[64] M. Asanuma,et al. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. , 2008, Current pharmaceutical design.
[65] D. Surmeier,et al. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. , 2008, Parkinsonism & related disorders.
[66] J. Gustafsson,et al. Liver X receptor β (LXRβ): A link between β-sitosterol and amyotrophic lateral sclerosis–Parkinson's dementia , 2008, Proceedings of the National Academy of Sciences.
[67] P. Riederer,et al. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability , 2008, Neurobiology of Disease.
[68] J. Mallet,et al. Neurotoxic Activation of Microglia Is Promoted by a Nox1-Dependent NADPH Oxidase , 2008, The Journal of Neuroscience.
[69] P. Mcgeer,et al. Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[70] B. Carleton,et al. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: A retrospective cohort study , 2008, Journal of Clinical Neuroscience.
[71] I Persson,et al. What is the harm-benefit ratio of Cox-2 inhibitors? , 2008, International journal of epidemiology.
[72] P. Brundin,et al. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease , 2008, Neurobiology of Disease.
[73] D. D. Di Monte,et al. Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease1 , 2008, The Journal of Immunology.
[74] R. Kuljiš,et al. The Role of Neuroimmunomodulation in Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.
[75] S. Sugama,et al. Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration , 2009, Journal of Neuroimmunology.
[76] E. Buerger,et al. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole , 2009, Current medical research and opinion.
[77] M. Tansey,et al. Neuroinflammation in Parkinson’s Disease , 2009, Journal of Neuroimmune Pharmacology.
[78] W. Wurst,et al. Regulation of astrocyte inflammatory responses by the Parkinson's disease‐associated gene DJ–1 , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[79] Mei Yu,et al. Elevated interleukin-1β induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice , 2009, Brain Research.
[80] M. Graeber,et al. Microglia: biology and pathology , 2009, Acta Neuropathologica.
[81] H. Kato,et al. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. , 2009, Experimental and molecular pathology.
[82] M. Niso-Santano,et al. Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. , 2009, Neurotoxicology.
[83] F. Bosetti,et al. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to β-amyloid , 2009, Aging.
[84] P. Gatev,et al. Interactions between cortical rhythms and spiking activity of single basal ganglia neurons in the normal and parkinsonian state. , 2009, Cerebral cortex.
[85] D. Souza,et al. Interleukin-6 Serum Levels in Patients with Parkinson’s Disease , 2009, Neurochemical Research.
[86] J. Cano,et al. Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not. , 2009, European journal of pharmacology.
[87] Peter Ponsaerts,et al. Microglia: gatekeepers of central nervous system immunology , 2009, Journal of leukocyte biology.
[88] M. Peter,et al. Selective types of autophagy in yeast. , 2009, Biochimica et biophysica acta.
[89] R. Niranjan,et al. Evaluation of guggulipid and nimesulide on production of inflammatory mediators and GFAP expression in LPS stimulated rat astrocytoma, cell line (C6). , 2010, Journal of ethnopharmacology.
[90] C. Haass,et al. Mitochondrial dysfunction in Parkinson's disease. , 2010, Biochimica et biophysica acta.
[91] S. Nah,et al. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration , 2010, Neurochemistry International.
[92] M. Goldberg,et al. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.
[93] A. Ghio,et al. Dopaminergic neurotoxicity following pulmonary exposure to manganese-containing welding fumes , 2010, Archives of Toxicology.
[94] F. Ciencias. Astrocyte-derived GDNF is a potent inhibitor of microglial activation , 2010 .
[95] R. Niranjan,et al. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6 , 2010, Free radical research.
[96] K. Suk,et al. Effects of Obovatol on GSH Depleted Glia-Mediated Neurotoxicity and Oxidative Damage , 2012, Journal of Neuroimmune Pharmacology.
[97] M. Cookson,et al. Astrocytes in Parkinson’s disease and DJ‐1 , 2011, Journal of neurochemistry.
[98] R. Akundi,et al. Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in Pink1-Deficient Mice , 2011, PloS one.
[99] M. Tansey,et al. TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. , 2011, Advances in experimental medicine and biology.
[100] E. Hirsch,et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism , 2011, Proceedings of the National Academy of Sciences.
[101] K. Tieu,et al. Astrocytes and therapeutics for Parkinson’s disease , 2010, Neurotherapeutics.
[102] L. Della Corte,et al. Anti-inflammatory actions of a taurine analogue, ethane β-sultam, in phagocytic cells, in vivo and in vitro. , 2011, Biochemical pharmacology.
[103] R. Niranjan,et al. Guggulipid and Nimesulide Differentially Regulated Inflammatory Genes mRNA Expressions via Inhibition of NF-kB and CHOP Activation in LPS-Stimulated Rat Astrocytoma Cells, C6 , 2011, Cellular and Molecular Neurobiology.
[104] F. Cicchetti,et al. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration , 2011, Journal of Neuroinflammation.
[105] J. Andersen,et al. Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression , 2011, Neurobiology of Disease.
[106] Sunhee C. Lee,et al. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR‐155 and miR‐155* , 2011, Glia.
[107] R. Niranjan,et al. Melatonin attenuated mediators of neuroinflammation and alpha-7 nicotinic acetylcholine receptor mRNA expression in lipopolysaccharide (LPS) stimulated rat astrocytoma cells, C6 , 2012, Free radical research.
[108] Xavier Golay,et al. Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[109] W. Poewe,et al. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy , 2012, Acta Neuropathologica.
[110] I. Krizbai,et al. Activation of Cannabinoid Receptor 2 Attenuates Leukocyte–Endothelial Cell Interactions and Blood–Brain Barrier Dysfunction under Inflammatory Conditions , 2012, The Journal of Neuroscience.
[111] J. Chavis,et al. Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. , 2012, Biochemical and biophysical research communications.
[112] S. Sugama,et al. Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies , 2012, Parkinson's disease.
[113] M. Burkovetskaya,et al. Neuroinflammation alters voltage-dependent conductance in striatal astrocytes. , 2012, Journal of neurophysiology.
[114] R. Niranjan,et al. The effect of guggulipid and nimesulide on MPTP-induced mediators of neuroinflammation in rat astrocytoma cells, C6. , 2012, Chemico-biological interactions.
[115] D. Walker,et al. Cobalt(II) β-ketoaminato complexes as novel inhibitors of neuroinflammation. , 2012, European journal of pharmacology.
[116] B. Barres,et al. Genomic Analysis of Reactive Astrogliosis , 2012, The Journal of Neuroscience.
[117] Mancheva-Ganeva Velina,et al. Licensed under Creative Commons Attribution Cc by Oxidative Stress in Parkinson's Disease , 2022 .